







an Open Access Journal by MDPI

# T-cell Immunity Assays in the Management of Cytomegalovirus (CMV) Infection

Guest Editor:

#### **Dr. Dimitrios Farmakiotis**

Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA

Deadline for manuscript submissions:

closed (31 July 2024)

## **Message from the Guest Editor**

Cytomegalovirus (CMV) infection is one of the most common opportunistic infections following organ or hematopoetic cell transplantation, and in patients with hematologic malignancies, especially those receiving alemtuzumab. CMV can also affect patients on high-dose steroids, the elderly, and other "immunomodulated", or even, rarely, immunocompetent individuals. Treatment for CMV, although effective, is associated with significant costs and toxicities. CMV-specific T-cell immunity (TCI) has been associated with protection against the virus, and reduced rates of CMV infection. In research studies, assays measuring CMV-specific TCI have been shown to be clinically useful in a variety of clinical scenaria, guiding initiation or discontinuation of anti-CMV prophylaxis or treatment. Nevertheless, there are still many answered questions regarding their potential utility in everyday clinical practice, or clinical-translational studies of CMV prevention (vaccines) or treatment, including adoptive Tcell immunotherapy.













an Open Access Journal by MDPI

### **Editor-in-Chief**

#### Prof. Dr. Andreas Kjaer

Department of Clinical Physiology, Nuclear Medicine & PET National University Hospital, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark

## **Message from the Editor-in-Chief**

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

#### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Internal Medicine)

#### **Contact Us**